Celivion campaign artwork: four women in evening wear seated together in a lamplit salon

Home / Professional

Company and product education

Celivion Lin J (hADM) product knowledge and specifications

This section presents product specifications, composition and material information for company and product education and preliminary promotion.

What is an hADM / acellular dermal matrix skin booster?

Product specifications

Product nameCelivion Lin J (also written Celivion LinJ in some catalogue lines)
MaterialMicronized human acellular dermal matrix (hADM)
Brand materials descriptionECM Skin Reviser
Presentation150 mg freeze-dried powder
Process namesAllo-PELT™ (Preserved ECM at Low Temperature Processed); ECM Mix Cage™
Particle profileMean 33.92 μm; D10 3.23 μm; D50 34.42 μm; D90 61.82 μm
Storage (catalogue)1–30°C
Residual DNA (listed analysis)40 ng/mg
Cytotoxicity viability (listed analysis)94.8%

Specifications are taken from the CELIVION product brochure and catalogue.

Composition data

Composition-analysis values: collagen ≈82.8%, elastin ≈4.7%, glycosaminoglycans (GAGs) ≈0.23%. Elastin relative to native skin is about 85.6%.

CELIVION LinJ

User Guide

For Healthcare Professionals Only

Made in Korea
Made in Korea
CELIVION LinJ 150mg

CELIVION LinJ Mixing Guide

CombinationProtocolTotal volumeIndication
BasicCELIVION LinJ 150mg + N/S 5cc5ccFull Face
+ HA (non-cross-linked)CELIVION LinJ 150mg + N/S 3.5cc + non-cross-linked HA 1.5cc5ccFull Face
+ HA (non-cross-linked)CELIVION LinJ 150mg + N/S 7.5cc + non-cross-linked HA 1.5cc9ccNeck
+ Lidocaine (2%)CELIVION LinJ 150mg + N/S 3cc + non-cross-linked HA 1.5cc + Lidocaine 0.5cc5ccFull Face

↔ Swipe horizontally to view the complete table

  1. Mixing steps 1
    1

    Fill a separate empty syringe with 5cc (or 3cc) of N/S. Then gently tap the LinJ syringe to loosen any clumped particles and remove any air inside.

  2. Mixing steps 2
    2

    Connect the two syringes using the provided connector, then push the N/S into the LinJ syringe.

  3. Mixing steps 3
    3

    Gently shake for about 2 minutes to ensure that LinJ and N/S are fully hydrated. Then disconnect the connector and remove any residual air.

  4. Mixing steps 4
    4

    (For combined treatment with HA, connect 1.5cc of HA and transfer it to the LinJ syringe.) Reconnect the connector and rapidly mix by alternately pushing the plungers back and forth at least 30 times.

  5. Mixing steps 5
    5

    Transfer all contents into the LinJ syringe, remove the connector, and attach the needle.

Check Point

  • Check the product condition immediately before use. If phase separation occurs, shake or tap the product thoroughly to remix it before use.
  • Insufficient mixing may cause particles to clump together or the needle to become clogged.
  • Please mix thoroughly according to the instructions.
Next-generation ECM Skin Reviser, CELIVION LinJ

For Healthcare Professionals Only

CELIVION LinJ Treatment Guide

Treatment areaInjection methodTarget layerDetails
FaceFaceNeedle 32~34G / 4mmDeep Dermis (45~60°)0.02~0.05ml/point
Cannula 23/25G / 5cmDeep Dermis (45~60°)0.1ml/stroke
Under-eye / Nasolabial / MarionetteUnder-eye / Nasolabial / MarionetteCannula 23/25G / 5cmImmediate Subdermis / Supraperiosteum ~ SubdermisUnder-eye: 0.5~0.8ml/side
Nasolabial: 1~1.5ml/side
NeckNeckNeedle 32~34G / 4mmDeep Dermis ~ Subcutaneous0.025ml/point
Left: 2ml / Center: 1ml / Right: 2ml
Cannula 25~26G / 5cmImmediate Subdermis5ml/side

↔ Swipe horizontally to view the complete table

  • Cannula-based treatment is recommended for the periorbital area and other areas with thin skin and frequent muscle movement.
  • Ensure that the injection is not too superficial and avoid injecting more than the recommended volume at any single injection point.
  • It is recommended to inject as close to the deep dermis as possible (deeper than Rejuran).
  • After injection, massage the treated area until the visible injection bumps disappear to ensure even product distribution.
  • Patients with a history of excessive skin booster treatments may have firmer tissue, requiring special care during injection.

Post-treatment Care & Management

  • Using LDM (ultrasound device) or performing manual acupressure massage within 5 minutes after treatment may help reduce swelling and promote product diffusion.
  • Please advise patients on the importance of proper skin moisturization to support treatment efficacy and skin regeneration.
  • Temporary erythema or swelling may occur after the procedure. If symptoms persist for more than 48 hours, please advise the patient to seek medical attention.
  • If swelling or erythema persists, symptoms usually improve within 1~2 days with oral antihistamines or oral corticosteroids.
  • Although CELIVION LinJ itself has a low potential for allergic reactions, local reactions may persist for longer in patients with underlying immune-related conditions.
  • Please obtain the patient’s medical history and history of previous treatments through a pre-procedure consultation.

Procedure video

Procedure guide video (Korean, 6 min 11 s) — Celivion Lin J procedure, Dr. Gyeongrak Lee, VERNI clinic. The clinic’s on-screen mixing captions are shown as recorded.

Safety & Quality

Laboratory listings and a facility licence.

They describe the tests and documents as presented in those materials.

Composition analysis

Collagenapprox. 82.8% 1
Elastinapprox. 4.7% 1
Elastin retention rate (versus native skin)approx. 85.6% 1
GAGs (glycosaminoglycans)approx. 0.23% 1

Decellularization markers

Residual DNA is listed as 40 ng/mg by ELISA, against a 50 ng/mg safety threshold cited in the same documentation. 2

Surfactant residue (Triton X-100) is listed as 0.004% (40 mg/kg) by HPLC-ELSD. 3

Collagen denaturation (FT-IR)

The listed average P2/P3 ratio for Celivion is 0.990 (standard deviation 0.023). The listing states that the closer the ratio is to 1, the less denaturation has occurred, and that a value of approximately 1.0 is described as intact collagen. This page reports the listed ratio. 4

In vitro cytotoxicity

An extraction test is listed with the method cited as ISO 10993-12, performed by KTR. Under the listed conditions — extraction 24 hours, 37°C, 120 rpm, L929 cells, incubation 48 hours — the Celivion value is 94.8% (MEM medium 100.0%, negative control 106.2%, positive control 11.4%). These are listed cell-viability figures for that test. The test-sample label visible in the source materials also records electron-beam sterilization at 15–30 kGy. 6

Serological screening

Screening covers ten serological tests, including HBV-NAT in addition to the nine tests referenced under Article 13 of Korea’s Human Tissue Act. The ten listed tests are: 7

  • HIV-1/2 Ab
  • HCV Ab
  • HBsAg
  • STS (RPR)
  • HTLV
  • HIV NAT (PCR)
  • HCV NAT (PCR)
  • HBcAb
  • HBsAb
  • HBV-NAT

Human tissue facility licence

An establishment licence was issued to BIOBIJOU Co., Ltd. ((주)바이오비쥬). Permit No. 336, from the Gyeongin Regional Office of the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea, is valid from 26 February 2026 to 25 February 2029. The licence type is tissue importer. Permitted activities are storage, distribution and import of bone, cartilage, fascia and skin. 8

This is a facility licence.

  1. Composition table; test data, Kmedihub Preclinical Research Center.
  2. Residual DNA 40 ng/mg and 50 ng/mg threshold; method labelled ELISA.
  3. Triton X-100 residue 0.004% (40 mg/kg), HPLC-ELSD; test data, Koptri (Korea Polymer Testing & Research Institute), Test report No. 25-01200, sample Koptri 25-07-0909-1.
  4. FT-IR P2/P3 average 0.990, SD 0.023; test data, KNU Kyungpook National University Center for Scientific Instruments.
  5. Particle profile; test data, Kyungpook National University Advanced Industrial Technology Institute.
  6. In vitro cytotoxicity; method cited as ISO 10993-12, KTR (Certified Testing Institute). The standard cited is the extraction / sample-preparation clause given in the source materials.
  7. Serological panel and HBV-NAT; a regulatory excerpt of Article 13(2) on blood-test items is included.
  8. Human tissue establishment licence; document shown, Permit No. 336, valid from 26 February 2026 to 25 February 2029, Gyeongin Regional Office of Food and Drug Safety.

FAQ

What is CELIVION Lin J?

Celivion Lin J is introduced as a micronized human acellular dermal matrix (hADM), presented as 150 mg freeze-dried powder. The brand materials description is ECM Skin Reviser.

What do the collagen, elastin and GAG figures mean?

Composition analysis lists about 82.8% collagen, 4.7% elastin and 0.23% GAGs.

What are D10, D50 and D90?

They are listed as 3.23 μm, 34.42 μm and 61.82 μm, with a mean particle size of 33.92 μm.

How can I request product information?

Email [email protected].

What is Allo-PELT™?

Allo-PELT™ (“Preserved ECM at Low Temperature Processed”) is the name of the low-temperature decellularization process used for Celivion Lin J. It is a stepwise low-temperature circulation system intended to retain ECM components, and it does not use acetic acid or pepsin. Process details and patent content are not disclosed.

What is ECM Mix Cage™?

ECM Mix Cage™ is the name of the particle step: milling, sizing and ratio management that turn the decellularized matrix into fine particles. It follows Allo-PELT™ decellularization. Technical details are not disclosed.

What surfactant residue was measured?

Triton X-100 residue was measured at 0.004% (40 mg/kg) by HPLC-ELSD, Koptri test report No. 25-01200, as reproduced in the product brochure.

What in-vitro cytotoxicity data are listed?

The listing shows 94.8% cell viability for the product extract (MEM medium 100.0%, negative control 106.2%, positive control 11.4%). The test by KTR used a 24-hour extraction at 37 °C, L929 cells and a 48-hour incubation, with sample preparation per ISO 10993-12 as given in the product brochure.

What residual DNA value is listed?

Residual DNA is 40 ng/mg (ELISA).

What is licence No. 336?

Licence No. 336 is a Korean tissue-bank establishment licence. It covers a tissue importer (storage, distribution and import, without processing) and is valid from February 26, 2026 to February 25, 2029.

How is hADM different from an HA filler?

HA fillers are based on hyaluronic acid gel. hADM is a different kind of material: a processed human dermal matrix made mainly of collagen, with elastin and GAGs.

How is it prepared?

See the user guide in the Product education.

How should it be stored?

Store at 1–30°C.

How can genuine product be identified?

For product traceability and verification information, email [email protected].

All questions for clinicians →

Company and product information

Company and product introduction

For company or product information, email [email protected]. This website is solely for education and preliminary promotion and does not accept online orders or payments.

Company and product information enquiries

For company or product information, email [email protected]. This website is solely for education and preliminary promotion and does not accept online orders or payments.

For company or product information, email [email protected]. This website is solely for education and preliminary promotion and does not accept online orders or payments.

[email protected]